Study guide

9.1 Principles of Casefinding & Facility Reference Dates

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

9.1 Principles of Casefinding & Facility Reference Dates

Key Takeaways Explain This Topic AI

Casefinding is the systematic, continuous screening of all healthcare facility diagnostic and treatment records to identify every reportable neoplasm.

Active casefinding, in which registry staff screen source documents themselves, produces far more complete and consistent ascertainment than passive casefinding, which relies on others to report cases.

The facility reference date is the immutable baseline start date (usually January 1 of a designated year) on or after which all eligible cases must be accessioned.

The Master Patient Index (MPI), suspense files, and accession register form the foundational operational tri-file system of the cancer registry.

A case diagnosed prior to the facility reference date is non-analytic and not reportable unless the patient develops a subsequent new primary diagnosed on or after that date.

Last updated: September 2026

9.1 Principles of Casefinding & Facility Reference Dates

Cancer casefinding is the operational foundation of every hospital-based and population-based cancer registry. Without a rigorous, comprehensive casefinding system, an oncology registry fails to fulfill its core surveillance and clinical benchmarking missions. For the Oncology Data Specialist (ODS-C), casefinding represents the first critical checkpoint in cancer data management: the systematic screening of healthcare facility data to identify all reportable neoplasms.

Definition and Strategic Goals of Cancer Casefinding

Casefinding (also termed case ascertainment) is defined as the systematic, organized method of identifying all patients diagnosed with or receiving initial or subsequent treatment for reportable neoplastic conditions within a specified healthcare facility or geographic catchment area.

Primary Operational Objectives

Completeness of Ascertainment: The primary objective of casefinding is capturing 100% of all reportable cases. Central registries are measured on completeness: NPCR's National Data Quality Standard and NAACCR Gold certification both require at least 95% completeness of case ascertainment. A hospital registry's casefinding is evaluated every year under its CoC Standard 6.1 quality control protocol, and it feeds the state's completeness.

Timeliness of Identification: Identifying cases early in their diagnostic and therapeutic course allows registries to capture concurrent clinical data, submit to the Rapid Cancer Reporting System (RCRS), and prevent abstracting backlogs. CoC Standard 6.4 requires monthly submission of new and updated cases, so casefinding must also be timely.

Data Integrity and Non-Duplication: Establishing whether a newly identified tumor represents a first lifetime diagnosis, a subsequent distinct primary malignancy, a disease recurrence, or a duplicate entry for an already accessioned patient.

Active vs. Passive Casefinding Methodologies

Healthcare facilities utilize two distinct operational models for cancer casefinding: active casefinding and passive casefinding . Understanding the operational, statistical, and staffing differences between these models is heavily emphasized on the national examination.

Operational Dimension Active Casefinding Passive Casefinding

Primary Personnel Credentialed Oncology Data Specialists (ODS-C) and dedicated registry casefinding staff. Attending physicians, nursing staff, clinical unit coordinators, or health records billing personnel.

Mechanism Registry staff independently and systematically query electronic source logs, disease indices, and pathology feeds. Registry relies on external clinical departments or individual providers to voluntarily notify or transmit charts.

Case Completeness High; the approach expected of accredited programs and central registries Lower and unpredictable; under-ascertains non-surgical, outpatient and elderly cases

Data Consistency High; standard reportability criteria and ambiguous terminology rules applied uniformly by specialists. Variable and subjective; external clinicians often misinterpret in situ lesions, non-malignant CNS tumors, or skin rules.

Labor & Cost Labor-intensive; requires dedicated registry FTE allocation and continuous technical workflow monitoring. Low initial administrative cost, but high long-term audit liability and heavy post-survey corrective workloads.

Regulatory Acceptability Gold standard; mandatory for CoC accreditation and standard central registry surveillance. Unacceptable as a standalone method for accredited programs; permitted only as an adjunctive notification feed.

Why Active Casefinding is the Standard of Care

In active casefinding, registry professionals do not wait for clinicians to report cases. The registry takes direct ownership of the surveillance net. A trained specialist navigates hospital electronic health records (EHRs), sets automated electronic laboratory triggers, audits monthly billing indices, and reconciles clinic rosters.

Conversely, passive casefinding suffers from severe selection bias. Busy clinicians frequently fail to report cases that are elderly, managed conservatively, managed palliatively without surgery, or enrolled in systemic clinical trials. In a purely passive system, the registry database skews heavily toward operative surgical cases, compromising epidemiological research and survival statistics.

The Facility Reference Date: Rules and Governance

The facility reference date is one of the most critical structural benchmarks in registry administration.

Definition

The facility reference date is defined as the formal, effective start date—almost universally established as January 1 of a designated calendar year (e.g., January 1, 2020)—on or after which all eligible reportable neoplasms diagnosed or receiving first-course therapy at the facility must be accessioned into the registry database. FACILITY REFERENCE DATE: JANUARY 1, 2020

  • │
  • PRE-REFERENCE PERIOD │ POST-REFERENCE PERIOD (ACTIVE SURVEILLANCE)
  • (Diagnosed Prior to Jan 1, 2020) │ (Diagnosed On or After Jan 1, 2020)
  • ───────────────────────────────────────────────────┼────────────────────────────────────────────────────────►
  • Case diagnosed in 2018: NON-ANALYTIC / EXCLUDED │ • Case diagnosed in 2020: ANALYTIC (Class 00, 10–22)
  • Admitted in 2022 for recurrence: NON-ANALYTIC │ • Diagnosed in 2023 at facility: ANALYTIC
  • CANNOT be counted as an analytic case │ • Full abstraction, staging, and follow-up required
  • Mandatory Reference Date Rules

Treat the Reference Date as a Stable Baseline: The CoC glossary defines the reference date simply as the "start date established for CoC accredited registries." Changing it (for example, moving it later to shrink the follow-up population) breaks trend and survival comparisons and affects the follow-up and NCDB populations, so any change needs cancer committee approval and CoC guidance. A new program must also start its registry early enough to supply a full calendar year of abstracted data before its first site visit; for example, the CoC lists a registry start date no later than January 1, 2025 for a 2027 site visit.

Pre-Reference Date Diagnoses: A tumor diagnosed before the reference date is not an analytic case . If the program chooses to accession it, STORE assigns Class of Case 35 (diagnosed before the reference date, with initial diagnosis and all or part of first-course treatment at the facility) or Class of Case 37 (diagnosed before the reference date, with initial diagnosis elsewhere and all or part of first-course treatment at the facility). CoC does not require these nonanalytic cases.

Subsequent Primary Exception: If a patient who was originally diagnosed prior to the reference date subsequently develops an entirely new, independent primary neoplasm diagnosed on or after the facility reference date , that subsequent primary neoplasm MUST be accessioned and abstracted as an analytic case.

Institutional Scope: The reference date applies across all inpatient pavilions, outpatient surgical centers, and ambulatory clinics operating under the facility's hospital provider number or CoC accreditation umbrella.

The Registry Tri-File Architecture: MPI, Suspense, and Accession Register

Efficient casefinding relies on three interconnected, foundational registry filing systems: ┌─────────────────────────────────────────────────────────────────────────┐

  • │ THE REGISTRY CASEFINDING TRI-FILE │
  • └───────────────────────────────────┬─────────────────────────────────────┘
  • │
  • ┌──────────────────────────────┼──────────────────────────────┐
  • ▼ ▼ ▼
  • ┌────────────────────────┐ ┌────────────────────────┐ ┌────────────────────────┐
  • │ MASTER PATIENT INDEX │ │ SUSPENSE FILE │ │ ACCESSION REGISTER │
  • │ • Permanent patient │ │ • Working holding queue│ │ • Indelible chronological│
  • │ historical database │ │ • Pending diagnostic │ │ log of all entries │
  • │ • Prevents duplicate │ │ confirmation/records │ │ • Unique Accession # │
  • │ accession numbers │ │ • Confirmed non-cases │ │ • Permanent lifetime │
  • │ • Tracks multiple │ │ dropped with audit │ │ identifier for │
  • │ primary neoplasms │ │ trail documentation │ │ patient records │
  • └────────────────────────┘ └────────────────────────┘ └────────────────────────┘
  • 1. Master Patient Index (MPI)

The Master Patient Index (MPI) is a permanent, cumulative database of every patient ever accessioned into the cancer registry, spanning both analytic and non-analytic cases.

Core Data Elements: Full legal name, maiden name/aliases, Social Security Number, medical record number (MRN), date of birth, sex, unique registry accession number, sequence numbers, primary anatomic sites, and initial diagnosis dates.

Operational Function: Whenever a potential case is identified during screening, the ODS queries the MPI first. This search determines whether the patient is already known to the registry. If the patient exists in the MPI, the specialist evaluates whether the current clinical event represents a recurrence/metastasis of a known primary or a brand new primary tumor requiring a new sequence number.

2. The Suspense File (Suspense List)

The Suspense File is the dynamic, temporary working queue that holds potential cancer cases identified during casefinding while awaiting diagnostic confirmation, complete pathology reports, or external clinical records.

Operational Lifecycle: A record enters suspense the moment a positive or suspicious casefinding hit occurs (e.g., an automated e-Path alert for "infiltrating ductal carcinoma" or an HIM disease index entry for "malignant neoplasm of colon").

Case Resolution: The ODS reviews medical records in suspense:

If the case is confirmed reportable, the specialist assigns an accession number, moves the case into the active abstracting queue, and clears the suspense item.

If subsequent biopsy or clinical workup proves the lesion is benign or non-reportable (e.g., biopsy reveals fibroadenoma, not carcinoma), the case is dropped from suspense with an auditable justification note .

Cases must not linger in suspense indefinitely. The registry's procedures set a review schedule (for example, a monthly aging report), and cases are followed back until they are confirmed or ruled out.

3. The Accession Register

The Accession Register is the permanent, indelible, chronological log of all cases formally accessioned into the cancer registry.

Accession Number Structure: STORE's Accession Number–Hospital [550] is nine digits: the first four are the year the patient was first seen at the facility for a reportable tumor, and the last five are the order in which the patient was accessioned that year (for example, 202600001 , 202600002 ).

Permanence of Assignment: Once an accession number is assigned to a patient, it belongs to that patient for life . Even if the patient develops three subsequent primary cancers over the next twenty years, the accession number never changes. Multiple tumors are differentiated by the Sequence Number (e.g., Sequence 00 for a solitary primary, or Sequences 01 and 02 for consecutive primaries).

Audit Rigor: An accession number can never be reassigned to another patient. If a case is accessioned in error and later voided upon discovery of a misdiagnosis, the accession number is retired with a documented void entry in the register to preserve the numerical sequence audit trail.

  • Practice Scenario & Exam Pitfalls
  • Clinical Practice Scenario

A 68-year-old male was diagnosed with invasive adenocarcinoma of the rectosigmoid colon at St. Jude Hospital on August 14, 2018, where he underwent a low anterior resection. St. Jude Hospital established its cancer registry with a facility reference date of January 1, 2020. On March 12, 2026, the patient presents to St. Jude Hospital with metastatic recurrence in the liver and begins systemic FOLFOX chemotherapy. The registry supervisor asks the ODS whether this patient should be accessioned as an analytic case for the 2026 reporting year.

ODS Regulatory Analysis: The original primary malignancy was diagnosed on August 14, 2018, which is prior to the facility reference date of January 1, 2020 . Under CoC and standard registry rules, a case diagnosed prior to the facility reference date cannot be accessioned as an analytic case, even if the patient receives treatment for recurrence at the facility after the reference date. The patient's 2026 chemotherapy represents treatment for recurrence of a pre-reference primary. If the program chooses to accession it, it is nonanalytic Class of Case 35 (diagnosed at the facility before the reference date). It is not required by CoC and cannot be counted toward the facility's analytic caseload. However, if this patient had developed a completely new primary (such as squamous cell carcinoma of the lung in 2026), that new lung primary would be fully reportable as an analytic case.

Core Exam Pitfalls to Avoid

Pitfall 1: Treating the reference date as a convenience setting. The reference date defines which cases are analytic for NCDB submission and follow-up. It is not changed casually, and pre-reference-date cases stay nonanalytic (Class of Case 35 or 37) even if they return for treatment.

Pitfall 2: Confusing the Accession Number with the Sequence Number. The accession number identifies the patient chronologically based on their first encounter year; the sequence number identifies the specific primary tumor across the patient's lifetime.

Pitfall 3: Failing to maintain an audit trail for dropped suspense cases. Suspense records that are determined to be non-reportable should not simply be deleted without documentation. Maintaining an auditable record of why a case was dropped prevents repeated screening re-entries and satisfies quality control reviews.

Loading diagram... Casefinding Identification, Suspense Triaging, and Registry File Integration